14 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 12 Phase 2, 8 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 3 | 8 | Completed 3, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 5 |
Follow amrubicin: new trials by email Literature Review of amrubicin trials Research Report on amrubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC) | Phase 3 | Active not recruiting | Amgen | 509 | 2023-05-31 | 2026-01-05 |
| Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer Pembrolizumab plus amurubicin - Small Cell Lung Cancer Extensive Stage | Phase 2 | Unknown | Wakayama Medical University | 25 | 2017-08-01 | 2020-05-19 |
| Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Nivolumab, Topotecan, Amrubicin - Lung Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 569 | 2015-09-14 | 2023-07-27 |
| A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe) - Small Cell Lung Cancer (SCLC) | Phase 2 | Terminated | Taiho Oncology, Inc. | 18 | 2013-07-01 | 2024-09-05 |
| Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Amrubicin - Soft Tissue Sarcoma | Phase 2 | Completed | University of Utah | 24 | 2011-09-01 | 2017-04-17 |
| Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma Amrubicin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Michaela Liedtke | 14 | 2011-08-01 | 2018-09-18 |
| A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Amrubicin - Thymoma, Thymus Cancer | Phase 2 | Completed | Heather Wakelee | 33 | 2011-06-01 | 2019-04-16 |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Amrubicin - Bladder Cancer | Phase 2 | Terminated | Matthew Galsky | 22 | 2011-02-01 | 2018-04-23 |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer Amrubicin, Carboplatin, Pegfilgrastim - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 81 | 2009-12-01 | 2016-05-05 |
| Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer Amrubicin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | SCRI Development Innovations, LLC | 78 | 2009-12-01 | 2022-05-03 |
| A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors. Amrubicin - Advanced Solid Tumors | Phase 1 | Completed | Celgene | 24 | 2009-06-01 | 2019-11-01 |
| Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies Amrubicin, Cyclophosphamide - Lung Cancer | Phase 1 | Completed | Lawrence Einhorn | 36 | 2009-03-01 | 2015-12-23 |
| Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Amrubicin Hydrochloride, Etoposide-Cisplatin combined chemotherapy - Lung Cancer | Phase 3 | Completed | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 300 | 2008-04-01 | 2014-07-18 |
| AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Amrubicin, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Celgene | 637 | 2007-09-01 | 2019-11-06 |
| Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer Amrubicin, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 2 | Completed | Celgene | 99 | 2006-11-01 | 2019-11-19 |
| Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy Amrubicin - Small Cell Lung Cancer | Phase 2 | Completed | Celgene | 75 | 2006-11-01 | 2019-10-24 |
| Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) Amrubicin Hydrochloride - Small-cell Lung Cancer | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 130 | 2006-04-01 | 2022-04-12 |
Showing 20 of 23. Sign in to see all of them.
Small Cell Lung Carcinoma (11) · Lung Neoplasms (5) · Breast Neoplasms (2) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1) · Thymoma (1) · Thymus Neoplasms (1) · Urinary Bladder Neoplasms (1)
Celgene (4) · Celgene Corporation (2) · SCRI Development Innovations, LLC (2) · AbbVie (1) · Amgen (1) · Bristol-Myers Squibb (1) · Daiichi Sankyo (1) · Gilead Sciences (1) · Heather Wakelee (1) · Japan Multinational Trial Organization (1) · Lawrence Einhorn (1) · Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (1) · Matthew Galsky (1) · Michaela Liedtke (1) · Sumitomo Pharma Co., Ltd. (1)
United States (17) · Japan (9) · Belgium (7) · Germany (7) · Italy (7) · France (6) · Netherlands (6) · Poland (6) · Spain (6) · United Kingdom (6) · Australia (5) · Austria (5) · Brazil (5) · China (5) · Greece (5)
Richard S Ungerleider, MD (3) · David R Spigel, M.D. (1) · Denise A. Yardley, M.D. (1) · Drug Development Division (1) · Giorgio Scagliotti, MD (1) · Heather A. Wakelee (1) · Hiroaki Akamatsu, M.D. (1) · Kaoru Kubota, MD, PhD (1) · Kazuhiko Nakagawa, M.D., Ph.D. (1) · Lawrence Einhorn, M.D. (1)
PMID 25503432, PMID 27061082, PMID 27597276, PMID 29802551, PMID 34590034, PMID 39530627, PMID 41055143, PMID 42377743
2015 (1), 2023 (1), 2025 (1)